Want to see AVXL full AI Analyst Report?
Top Page
Anavex Life Sciences
(NASDAQ:AVXL)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▼(-52.08% Downside)
Action:Reiterated
Date:10/21/26
The score is weighed down primarily by weak financial durability (no revenue and ongoing cash burn despite some TTM improvement) and very bearish technicals with the stock far below major moving averages. Valuation provides little support given losses and no dividend.
Positive Factors
Debt-free balance sheet
The absence of reported debt limits refinancing pressure and interest obligations, giving Anavex greater flexibility while it funds clinical development. Although the company remains loss-making, a debt-free structure can help preserve strategic options and reduce the severity of financial stress during a prolonged development cycle.
Negative Factors
No commercial revenue
The absence of reported revenue means Anavex has not yet demonstrated commercial product demand or recurring operating income. Until a candidate is approved and launched, financial performance will remain dependent on research progress and external financing rather than a self-sustaining revenue base, limiting earnings visibility over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of reported debt limits refinancing pressure and interest obligations, giving Anavex greater flexibility while it funds clinical development. Although the company remains loss-making, a debt-free structure can help preserve strategic options and reduce the severity of financial stress during a prolonged development cycle.
Read all positive factors
Anavex Life Sciences (AVXL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$123.29M
Dividend YieldN/A
Average Volume (3M)1.26M
Price to Earnings (P/E)―
Beta (1Y)2.06
Revenue GrowthN/A
EPS Growth73.28%
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding92,696,840
10 Day Avg. Volume1,309,488
30 Day Avg. Volume1,256,348
Financial Highlights & Ratios
PEG Ratio-4.29
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$1.21B
Anavex Life Sciences Business Overview & Revenue Model
Company Description
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanc...
How the Company Makes Money
Anavex Life Sciences is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not have a broad, recurring commercial product revenue base comparable to an established pharmaceutical manufacturer. The comp...
Anavex Life Sciences Earnings Call Summary
Earnings Call Date:Feb 09, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 30, 2026
Earnings Call Sentiment Positive
The call presents a cautiously optimistic tone: the company reports a strong cash position with multi-year runway, notable reductions in burn, positive clinical signals (especially in the AB-clear precision-medicine subgroup) and constructive regulatory engagement with the FDA. However, the CHMP negative opinion, a missed ADCS-ADL endpoint in the original EU submission, and remaining execution and regulatory obligations (including potential confirmatory post-approval studies) are meaningful near-term risks. Overall, positive operational and scientific developments outweigh the regulatory setbacks, but outcomes remain contingent on ongoing reexamination and further regulatory interactions.Positive Updates
Strong cash position and runway
Cash of $131.7 million at Dec 31 with no debt; cash used in operating activities of $7.1 million during the quarter; company anticipates cash runway of more than three years at current burn rate.
Negative Updates
CHMP negative opinion and regulatory uncertainty in EU
In December the CHMP adopted a negative opinion on the marketing authorization application for blarcamesine; company has requested EMA reexamination and expects the reexamination process to occur during the first half of the year (company described a 60+60-day response/review sequence plus rapporteur review). Approval is not guaranteed.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong cash position and runway
Cash of $131.7 million at Dec 31 with no debt; cash used in operating activities of $7.1 million during the quarter; company anticipates cash runway of more than three years at current burn rate.
Read all positive updates
Company Guidance
On the fiscal 2026 Q1 call (Feb 9, 2026) management gave specific operational and regulatory guidance: cash was $131.7M at Dec 31 with no debt and $7.1M of cash used in the quarter, implying a stated cash runway of more than three years at the current burn; Q1 R&D was $4.7M (down from $10.4M YoY) and G&A was $2.1M (down from $3.1M YoY), with a net loss of $5.7M or $0.06 per share; regulatory timelines include an EMA re‑examination process described as a 60+60‑day response window plus an additional ~60‑day rapporteur review (targeted in H1 2026) and a January Type C meeting with the FDA after which the company will submit the full Phase 2b/3 (Anavex 2‑73 AD‑004) data package toward next steps/NDA planning; programmatic updates include participation in the multiyear, EC‑funded Access AD initiative and a planned AD‑006 placebo‑controlled study in early AD, ongoing compassionate use in Rett and AD (Canada, UK, Australia), presentations/publications (CTAD, March 12 Johns Hopkins), pursuit of a CMA with a confirmatory post‑approval study if granted, and biomarker/genetic findings (COL24A1 prevalence estimated >70% in early AD) plus advancement of Anavex 3‑71 toward pivotal schizophrenia studies.Anavex Life Sciences Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -21.81M | -46.38M | -43.00M | -46.54M | -47.62M | -37.64M |
| Net Income | -24.04M | -46.38M | -43.00M | -47.51M | -47.98M | -37.91M |
Balance Sheet | ||||||
| Total Assets | 120.14M | 103.81M | 135.57M | 154.39M | 152.70M | 161.62M |
| Cash, Cash Equivalents and Short-Term Investments | 118.33M | 102.58M | 132.19M | 151.02M | 149.16M | 152.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.69M | 8.95M | 15.30M | 12.53M | 10.21M | 10.80M |
| Stockholders Equity | 112.45M | 94.87M | 120.26M | 141.85M | 142.49M | 150.82M |
Cash Flow | ||||||
| Free Cash Flow | -33.73M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Operating Cash Flow | -33.73M | -39.04M | -30.81M | -27.79M | -24.24M | -30.38M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 46.57M | 9.43M | 11.97M | 29.65M | 21.29M | 153.24M |
Anavex Life Sciences Technical Analysis
Negative
3.13
Price Trends
2.34
Negative
2.51
Negative
3.17
Negative
Market Momentum
-0.29
Negative
23.02
Positive
51.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVXL, the sentiment is Negative. The current price of 3.13 is above the 20-day moving average (MA) of 1.61, above the 50-day MA of 2.34, and below the 200-day MA of 3.17, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 23.02 is Positive, neither overbought nor oversold. The STOCH value of 51.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVXL.
Anavex Life Sciences Risk Analysis
Anavex Life Sciences disclosed 54 risk factors in its most recent earnings report. Anavex Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anavex Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $409.88M | -1.45 | -178.58% | ― | 287.93% | -21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $321.71M | -7.47 | 21.48% | ― | ― | 33.25% | |
46 Neutral | $174.53M | -1.68 | -51.01% | ― | ― | 56.00% | |
45 Neutral | $251.38M | -14.31 | -5.76% | ― | ― | 93.45% | |
41 Neutral | $123.29M | -5.09 | -21.11% | ― | ― | 73.28% | |
38 Underperform | $76.17M | -1.61 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
AVXL
Anavex Life Sciences
1.33
-7.16
-84.33%
GALT
Galectin Therapeutics
3.19
-1.91
-37.45%
RCKT
Rocket Pharmaceuticals
2.29
-1.65
-41.88%
CLLS
Cellectis SA
0.98
-2.65
-73.00%
AUTL
Autolus Therapeutics
1.54
-0.11
-6.67%
PEPG
PepGen Inc.
2.52
-2.91
-53.59%
Anavex Life Sciences Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Anavex Advances Blarcamesine Clinical Pharmacology and Rare-Disease Programs
Positive
Oct 20, 2026
On October 20, 2026, Anavex reported completion of the clinical conduct of two key pharmacology studies of blarcamesine—an ADME study and a drug-drug interaction study—in healthy volunteers, with no serious adverse events observed in p...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Anavex IND Cleared for Fragile X Syndrome Trial
Positive
Oct 15, 2026
On October 15, 2026, Anavex Life Sciences said the U.S. Food and Drug Administration cleared its Investigational New Drug application, allowing the company to begin clinical testing of blarcamesine in Fragile X syndrome in the United States. The d...
Executive/Board ChangesShareholder Meetings
Anavex Shareholders Back Board Slate in Contested Meeting
Positive
Sep 28, 2026
On September 24, 2026, Anavex Life Sciences held its Annual Meeting, at which 54,239,204 shares, representing about 58.51% of outstanding common stock as of the July 31, 2026 record date, were present or represented by proxy. The meeting featured ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Anavex Advances Rett Syndrome Phase 3 Trial Plans
Positive
Sep 9, 2026
On September 9, 2026, Anavex Life Sciences reported progress in its clinical program for ANAVEX 2‑73 in Rett syndrome, as it moves ahead with a Phase 3 trial in adult patients under the study designation ANAVEX 2‑73‑RS‑005....
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Anavex Regains Nasdaq Compliance, Stock Listing Secured
Positive
Sep 2, 2026
On May 20, 2026, Anavex Life Sciences received a delinquency notice from Nasdaq after failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The company submitted a compliance plan on July 20, 2026, and subsequently filed its o...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Anavex Board Urges Shareholders to Support Slate
Positive
Aug 17, 2026
On August 17, 2026, Anavex Life Sciences announced that its board’s Executive Committee had mailed a letter to stockholders ahead of the 2026 Annual Meeting, urging them to vote the white proxy card in favor of all six director nominees. The...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Anavex Life Sciences Files Proxy, Urges Director Support
Neutral
Aug 11, 2026
On August 11, 2026, Anavex Life Sciences announced it had filed definitive proxy materials with the SEC for its 2026 Annual Meeting of Stockholders, scheduled for September 24, 2026, and began mailing a letter urging investors to support all six o...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Anavex Refreshes Board, Emphasizes Governance and Pipeline Focus
Negative
Aug 3, 2026
On August 3, 2026, Anavex Life Sciences announced plans to refresh its Board of Directors ahead of the 2026 Annual Meeting, nominating two new independent directors, investment executive Gautam Patel and pharmaceutical veteran Dr. Adrian Senderowi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.